> Skip repeated content

Ropivacaine Analgesia via an Intra-articular Infusion after Total Knee Arthroplasty – A Prospective, Randomized, Blinded, Placebo-Controlled Trial

IRB Number: 10049
inactive

August 03, 2010

Institutional Review Board, Hospital for Special Surgery

The safety of our participants is our top priority. The trial/study is approved and periodically reviewed by the Institutional Review Board (IRB), which includes doctors, administrators, ethicists, and members of the general public. The safety of clinical trials is reviewed by the U.S. Food and Drug Administration.

Before enrolling in a clinical trial or research study, the investigator will explain the purpose of the trial/study, its expected benefits, any possible risks or side effects, and what your role will be. If you want to join the trial/study, you must sign informed consent documents. You can leave a trial/study at any time without penalty.

For further information, see Understanding Clinical Trials/Research Studies.

Principal Investigator

Charles N. Cornell, M.D.

Co-Investigators

Keith R. Reinhardt M.D.
Denis Nam M.D.
Spencer S. Liu M.D.

Summary

112 patients with at least 12 month follow-up.  Enrollment period 2 years.

Inclusion/Exclusion Criteria

All patients 18- 80 years old with mono-articular knee osteoarthritis indicated for tricompartment primary total knee replacement.

Contact Information

Charles N. Cornell, M.D.
cornellc@hss.edu
212.606.1414